A c c e p t e d M a n u s c r i p t 6 invasive candidiasis, the shifting species distribution of Candida infections, the emergence of 1 antifungal resistance and the limitation of the current arsenal of antifungal agents. Amphotericin B binds directly to ergosterol, the component of the fungal plasma membrane, 6 and thereby causes the leakage of intracellular potassium and magnesium [39] . It is by far the 7 most potent antifungal agent for systemic candidiasis, and has been regarded as the 'gold 8 standard' [40] . Amphotericin B has a broad spectrum and fast onset of activity [41, 42] . However, it is associated with adverse nephrotoxicity that is cumulative and might not be Pyrimidines. Flucytosine (or 5-fluorocytosine) is a synthetic compound, which was originally 13 synthesized in 1957 as a potential antitumor drug; however, its antifungal activity was later 14 discovered and it was used to treat candidiasis from 1968 [46, 47] . Flucytosine is converted to properties as outlined below [60, 61] (Table 3 ). An ideal antifungal agent for Candida 8 infections should have a broad spectrum of activity (within the Candida genus), no 9 resistance, an ideal pharmacokinetic and pharmacodynamic profile and no toxicity or side 10 effects.
11
Broad spectrum of activity within the Candida genus
12
Broad-spectrum antifungal agents, which are effective against a wide range of species in the 13 fungus kingdom, are traditionally preferred, because this allows empirical therapy and the 14 start of treatment before the species identification of the responsible pathogen [62] . Recently, 15 it has been suggested that molecules with narrow-spectrum antifungal activity could be of 16 significant value and should not be neglected [63, 64] . Narrow-spectrum antifungals that are 17 effective against certain fungal genera would enable the rational use of antifungals and, A c c e p t e d M a n u s c r i p t High-throughput screening of small molecules is advantageous to antifungal drug discovery. Hit-to-lead and lead optimization 16 Hits are defined as the positive output of a screen having sufficient potency and are of known 17 structure. Some of the hits identified from the primary screening can be false positives.
18
Therefore, a secondary screen (hit validation) is required for validation to ensure that the 19 resulting phenotype was caused by the responsible small molecule.
20
Leads are defined as the molecules, on top of the potency, with sufficient potential (e.g.
21
pharmacokinetics, specificity, patentability) to be developed as drugs [96] . One of the reasons for the slow progress in this field is the eukaryotic nature of fungi. This is 6 a major hurdle in development of antifungals because they carry substantial similarities to 7 human cells. Therefore, finding a suitable fungal-specific drug target is not a trivial task.
8
Cell wall
9
The cell wall has remained an attractive area of study as an antifungal drug target, because it 10 comprises a number of key molecules that are not present in humans. The cell wall is an
11
essential Candida component and is the first contact site of the pathogen with the host [106] .
12
The C. albicans cell wall is rich in carbohydrate, and mainly comprises glucose (glucans), N- 
15
In another study, a microplate-based morphological screening assay was performed to find A c c e p t e d M a n u s c r i p t wide range of Candida species. In vivo, SM21 is able to treat systemic and oral candidiasis in 7 murine models. The exact mechanism of action of SM21 is still to be elucidated.
8

Concluding remarks 9
The serious threat that Candida infections are posing to public health urgently requires rapid 
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